Trials Sponsors Conditions Drugs Pricing

Conditions

Obesity & Overweight obesity

Outcome Measures

Primary Outcomes (2)

Change in Body Mass Index (BMI) after semaglutide treatment
Change in BMI between baseline and 6 months after initiation of semaglutide treatment, expressed in kg/m²
From enrollment to the end of treatment at 6 months
Change in Binge Eating Scale (BES) score after semaglutide treatment
Change in BES score between baseline and 6 months after initiation of semaglutide treatment. Score range: 0 to 46 points
From enrollment to the end of treatment at 6 months

Study Arms (1)

To identify for whom semaglutide works best across the binge eating spectrum

EXPERIMENTAL

Semaglutide 3,2 mg/ml (Wegovy®)

Drug: Semaglutide 3,2 mg/ml

Interventions

Semaglutide 3,2 mg/mlDrug

Starting dose is 0.25 mg once a week, escalated every four weeks until the maximal dose of 2.4 mg per week or the highest tolerated dose is reached, which will be maintained until the end of the Trial. Route of administration: subcutaneous in the abdomen, thigh or upper arm.

To identify for whom semaglutide works best across the binge eating spectrum

Wegovy 2.4 mg FlexTouch solution for injection in pre-filled penType not reported

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Formulated product
Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry record

Ingredients named in source formulations

The registry names these ingredients. The formulation’s exact chemical form has not been confirmed.

Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen
Named ingredient: Semaglutide
View registry record

Eligibility Criteria

Age18 Years - 65 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
At least 18 years of age and under 65 years of age at the time of signing the informed consent form (ICF)

Sponsors & Collaborators

Universitaire Ziekenhuizen KU Leuven
Otherlead
UZ Leuven
Type not reportedlead

Study Sites (1)

UZ/KU Leuven

Leuven, 3000, Belgium

RECRUITING

MeSH Terms

Conditions

ObesityOverweight

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Roman Vangoitsenhoven, Prof. Dr.

CONTACT

+3216193235 roman.vangoitsenhoven@uzleuven.be

Nathalie Weltens, PhD

CONTACT

+32 16 37 74 86

Study Design

Study Type: interventional
Phase: phase 4
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

July 20, 2026

First Posted

October 13, 2026

Study Start

August 26, 2026

Actual (reported)

Primary Completion

December 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

You may not qualify if:

Any form of diabetes mellitus (T1- or T2DM), defined as current hemoglobin A1c (HbA1c) \> 6.5% or the use of antihyperglycemic drugs (metformin is permitted if prescribed for an indication other than T2DM and at a stable dose for at least 3 months days prior to screening)
Use of incretin-based drugs, including GLP-1RAs (including dual agonists) and dipeptidyl peptidase-4 (DPP-4) inhibitors or amylin analogues within 3 months prior to screening
Contraindications for semaglutide: history of pancreatitis, medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)
Chronic kidney disease 3b or worse, defined as estimated Glomerular Filtration Rate (eGFR) \< 45 ml/min/1.73m²
Previous bariatric surgery
Disorders known to affect DA signaling significantly, including movement disorders such as Parkinson's disease, prolactinoma, paraganglioma, pheochromocytoma
Active use of medication affecting DA signaling, including antiparkinson medications, attention deficit hyperactivity disorder (ADHD) medications, antipsychotics, naltrexone-bupropion for weight management or antidepressants; use of serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), or trazodone is permitted if participants are on a stable dose for at least three months. Incidental use of antiemetics or sedative hypnotics is allowed but not within 48 hours prior to a study visit
Current or recent (within the past 6 months) clinically significant alcohol or drug misuse (excluding nicotine) that, in the investigator's judgment, may compromise participant safety or the integrity of study data.
Active severe neuropsychiatric disorders, including dementia, psychotic disorder, bipolar disorder and severe depression
Acute suicidality or history of suicide attempt within 5 years prior to screening
Any condition or major illness which, in the investigator's opinion, may jeopardise participant safety or compliance with the protocol
Unable to understand the risks, realistic benefits and compliance requirements of each program
Unwillingness to be informed about incidental findings that may be important for the participant's health
Recent participation (\< 30 days) or simultaneous participation in an interventional Trial with an investigational medicinal product (IMP) or device
If applicable: Female who is pregnant, breast-feeding or intends to become pregnant in the following 6 months or is of childbearing potential and not using an adequate, highly effective contraceptive
+3 more criteria

A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Study Arms (1)

To identify for whom semaglutide works best across the binge eating spectrum

Interventions

Registry intervention entries

Ingredients named in source formulations

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source records

Documents

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Study Arms (1)

To identify for whom semaglutide works best across the binge eating spectrum

Interventions

Registry intervention entries

Ingredients named in source formulations

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source records

Documents

Locations